This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Earnings Preview: AngioDynamics (ANGO) Q1 Earnings Expected to Decline
by Zacks Equity Research
AngioDynamics (ANGO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
AngioDynamics Unveils Auryon Atherectomy System for PAD
by Zacks Equity Research
AngioDynamics' (ANGO) Auryon Atherectomy System leverages breakthrough technology to deliver treatment of PAD lesions and occlusions.
Why Is AngioDynamics (ANGO) Down 1.3% Since Last Earnings Report?
by Zacks Equity Research
AngioDynamics (ANGO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
New Strong Sell Stocks for August 5th
by Zacks Equity Research
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today
New Strong Sell Stocks for August 3rd
by Zacks Equity Research
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today
AngioDyanamics (ANGO) Reports Q4 Loss, Revenues Lag Estimates
by Zacks Equity Research
AngioDyanamics (ANGO) witnessed revenue decline across all business segments in Q4.
AngioDynamics (ANGO) Reports Q4 Loss, Lags Revenue Estimates
by Zacks Equity Research
AngioDynamics (ANGO) delivered earnings and revenue surprises of -20.00% and -6.28%, respectively, for the quarter ended May 2020. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate AngioDynamics (ANGO) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
AngioDynamics (ANGO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Buy These 5 Low Leverage Stocks to Avoid Debt-Related Risk
by Zacks Equity Research
Exorbitant debt financing might even cause a corporation's bankruptcy in the worst-case scenario.
Here's Why You Should Add AngioDynamics to Your Portfolio
by Zacks Equity Research
AngioDynamics (ANGO) continues to benefit from strategic buyouts and strong product portfolio.
AngioDynamics (ANGO) Down 1.6% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
AngioDynamics (ANGO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Quest Diagnostics Grows on New Tests Amid Coronavirus Crisis
by Zacks Equity Research
Quest Diagnostics' (DGX) new COVID-19 tests start adding to its Diagnostic information Services business sales.
AngioDyanamics (ANGO) Q3 Earnings and Revenues Top Estimates
by Zacks Equity Research
AngioDynamics (ANGO) fiscal third-quarter results benefit from strong growth across all businesses and higher revenues.
AngioDynamics (ANGO) Beats Q3 Earnings and Revenue Estimates
by Zacks Equity Research
AngioDynamics (ANGO) delivered earnings and revenue surprises of 133.33% and 1.98%, respectively, for the quarter ended February 2020. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: AngioDynamics (ANGO) Q3 Earnings Expected to Decline
by Zacks Equity Research
AngioDynamics (ANGO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
AngioDynamics (ANGO) Upgraded to Buy: Here's What You Should Know
by Zacks Equity Research
AngioDynamics (ANGO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
AngioDynamics (ANGO) Down 10.4% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
AngioDynamics (ANGO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Here's Why You Should Hold on to AngioDynamics Stock Now
by Zacks Equity Research
AngioDynamics (ANGO) retains fiscal 2020 view; VA revenues soft in fiscal Q2.
AngioDynamics (ANGO) Q2 Earnings Top, Revenues Lag Estimates
by Zacks Equity Research
AngioDynamics (ANGO) gains from core Oncology business in the fiscal second quarter, reiterates guidance.
AngioDynamics (ANGO) Beats Q2 Earnings Estimates
by Zacks Equity Research
AngioDynamics (ANGO) delivered earnings and revenue surprises of 200.00% and -2.61%, respectively, for the quarter ended November 2019. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: AngioDynamics (ANGO) Q2 Earnings Expected to Decline
by Zacks Equity Research
AngioDynamics (ANGO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Why Is AngioDynamics (ANGO) Up 0.9% Since Last Earnings Report?
by Zacks Equity Research
AngioDynamics (ANGO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
AngioDynamics Boosts VIT Product Portfolio With New Buyout
by Zacks Equity Research
AngioDynamics (ANGO) is likely to see an expansion of its already existing VIT product portfolio with the buyout of Eximo Medical.
AngioDynamics (ANGO) Q1 Earnings Top, Revenues Lag Estimates
by Zacks Equity Research
AngioDynamics (ANGO) keeps fiscal 2020 revenue guidance intact, slashes EPS view.
Luminex Gets FDA Nod for ARIES MRSA Assay, Boosts Platform
by Zacks Equity Research
Luminex (LMNX) receives FDA clearance for the ARIES MRSA assay, which is likely to provide a boost to the company's ARIES platform.